Crown Bioscience Appoints Guy Sheets as Senior Vice President, Commercial
Crown Bioscience appointed Guy Sheets as Senior Vice President, Commercial, bringing over 30 years of pharma and life sciences experience to lead the CRO's global commercial strategy. Sheets previously held senior commercial roles at QPS Holdings, CenExel, SGS Health Sciences, Lonza, and Thermo Fisher Scientific.
This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.
Free workspace
Turn your Sciences expertise into content.
Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.
Crown Bioscience, a global contract research organization (CRO) specializing in oncology drug discovery and development, today announced the appointment of Guy Sheets as Senior Vice President, Commercial.
Guy will lead Crown Bioscience’s global commercial strategy, with responsibility for driving growth, expanding market presence, and strengthening client partnerships. He will work closely with scientific and operational leaders to connect the company’s preclinical and translational research capabilities with the evolving needs of biotechnology and pharmaceutical clients.
Guy brings more than 30 years of commercial leadership experience across the pharmaceutical, biotechnology, and life sciences industries. Most recently, he served as Vice President, Head of Global Business Development at QPS Holdings, leading commercial organizations supporting preclinical and clinical contract research services. He previously held senior leadership positions at CenExel Clinical Research, SGS Health Sciences, and Lonza, with earlier roles at Thermo Fisher Scientific and SCHOTT.
“Guy brings extensive experience in research services and a strong track record of building high-performing global commercial teams, and a deep commitment to developing lasting client partnership,” said John Gu, Chief Executive Officer of Crown Bioscience. “His leadership will help us strengthen our global commercial organization, deepen customer engagement and better align our scientific expertise with evolving clients’ needs as we enter our next phase of growth.”
About Crown Bioscience
Crown Bioscience is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to deliver integrated preclinical and translational research solutions, supporting programs from target discovery through clinical development.
Our portfolio includes more than 2,800 patient-derived xenograft (PDX) models and approximately 1,000 tumor organoid models across 35 cancer indications, supported by expertise in in vivo, in vitro, ex vivo, and in silico research.
Combined with advanced laboratory services, multiomics capabilities, and data science, we help generate the insights needed to support confident decision-making throughout the drug development continuum.
Operating from 9 facilities across the US, Europe, and APAC, our laboratories meet the highest industry standards and include CAP-, CLIA-, and ISO 15189-accredited facilities. To learn more, visit www.crownbio.com.
Your experts belong here
Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.
Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.
About the author
